Don and management is our biggest risk for RVX. The company is undervalued and management is to blame NO DOUGHT. I would like to quote Buffett: "The number one risk factor, you never see it, the number one risk factor is that this business gets the wrong management, and you get a guy or a woman in charge of it that are personable, the directors like them, they don't know what they're doing, but they know how to put on an appearance. That's the single biggest danger," Buffett said during Berkshire Hathaway's annual meeting of shareholders on Saturday."
t
Saudi deal BS Don.... whats new with that, at least one of the existing SH stepped up, overall not bad deal but get it rolling ASAP.
C
A post I read today. Almost too good to be true? If I heard this story at a bus stop or in the back seat of a taxi, I would be noding my head with you right now with a smurk on my face saying "yeah...the poster child story for 'too good to be true!'".
Thing is though, I heard of RVX through a respected source and I am afflicted with a curiosity that could extinct cats, and a healthy confidence that I can understand just about anything conceivable if I persist.  To say that my curiosity has been consistently peaked would be a massive understatement. Every time I delve deeper and deeper into this wonder drug I become more and more captivated and amazed. I feel like Roy Neary (played by Richard Dreyfuss) in the movie Close Encounters of the Third Kind where he becomes increasingly "possessed" and is increasingly self-validated with each day's discovery.
This curiosity (and thanks to a lot of time on my hands) has allowed me to discover very promising study information from a multitude of highly-respected scientific sources. Â
I have accumulated a massive amount of scientific data and studies that supports the potential, the probability even, that apabetalone will be the most widely used drug in the world, one day. I have at least some proof if not strong indications of safety and effectiveness for each of the indications below. Maybe one day I will drop a "super-post" on you all with my favorite promising evidence for each indication below. Â
Too good to be true? This guy doesn't think so.
APABETALONE (RVX-208) - ONE DRUG - MANY CURES:  Covid19 (and possibly most if not all coronavirus) Cardiovascular Disease (CVD) Chronic Kidney Disease (CKD) Alzheimer Disease (AD) DIABETES MILITUS (DM) FABRY DISEASE COLORECTAL CANCER LIVER CANCER OVARIAN CANCER (Chemotherapy resistant) HIV-1 (AIDS) MUSCULAR DYSTROPHY (FSHD) RESTENOSIS Osteoporosis Friedreich’s Ataxia Thrombosis Pulmonary arterial hypertension PAH Degenerative diseases of the eye (retinal) PERIODONTAL DISEASES NASH (non-alcoholic steatohepatitis) ASTHMA Paroxysmal nocturnal hemoglobinuria (PNH) ARTHRITIS Calciphylaxis Complement Mediated Disease Neurofibromatosis - Malignant Peripheral Nerve Sheath Tumors (MPNST) Sepsis, sepsis shock and MODS (Multiple Organ Dysfunction Syndrome in Sepsis)
t
Another cheap exempt distribution at 0.85CAD and warrant at $1 until 2024 for 2.5M, Great Job Don evaluating the company so cheap again. Wonder why the Saudi did not close. Amazing Science team with Car salesman to represent.
C
We start immediate testing for ABL and Covid. .93 really
C
Again good news on Covid front and we go down. Just sell the company
C
Apabetalone and RVX-297 Apabetalone (also known as RVX-208 or RVX-000222), an oral BETi selective for BD2 within BETs, is currently used in phase 3 clinical trials for the treatment of coronary artery disease, diabetes, and chronic kidney failure. In a mouse model of lethal endotoxemia, apabetalone prevents liver damage by inhibiting the expression of alpha-2-macroglobulin and serum amyloid P. In patients with cardiovascular disease, apabetalone provides benefit for limiting chronic cytokine signaling (Wasiak et al., 2020). Thus, this action of apabetalone might also serve as an effective therapy in treating patient with sepsis and MODS, especially sepsis-induced cardiomyopathy. BRD2 is a direct target of apabetalone (Gordon et al., 2020). Since apabetalone can inhibit the expression of angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the SARS-CoV-2 particles to gain entry into human cells, it is becoming a promising drug for the treatment of COVID-19 and concomitant sepsis (Gilham et al., 2020). RVX-297, a 4-quinazolinone derivative related to RVX-208, is two times more selective for BD2 than RVX-208. RVX-297 also decreases the production of multiple cytokines in endotoxemic mice (Jahagirdar et al., 2017), highlighting its potential anti-inflammatory activities in lethal infection.
WOW. With the news coming out of Australia I thought there might be some interest here. Maybe it will come soon.
r
Clearly the volume is low but moving, The problem is people that re in have lost confidence and are dumping but this stock should go up. Just need some better publicity as there is really positive news on this drug and it will help the world. Be patient.... Ive been here for a long time and am not giving up now.
C
Based on this news we should be dosing Covid patients who get into hospital. We’d know pretty quickly if it works. And maybe prevent people going into ICU.
If I heard this story at a bus stop or in the back seat of a taxi, I would be noding my head with you right now with a smurk on my face saying "yeah...the poster child story for 'too good to be true!'".
Thing is though, I heard of RVX through a respected source and I am afflicted with a curiosity that could extinct cats, and a healthy confidence that I can understand just about anything conceivable if I persist.  To say that my curiosity has been consistently peaked would be a massive understatement. Every time I delve deeper and deeper into this wonder drug I become more and more captivated and amazed. I feel like Roy Neary (played by Richard Dreyfuss) in the movie Close Encounters of the Third Kind where he becomes increasingly "possessed" and is increasingly self-validated with each day's discovery.
This curiosity (and thanks to a lot of time on my hands) has allowed me to discover very promising study information from a multitude of highly-respected scientific sources. Â
I have accumulated a massive amount of scientific data and studies that supports the potential, the probability even, that apabetalone will be the most widely used drug in the world, one day. I have at least some proof if not strong indications of safety and effectiveness for each of the indications below. Maybe one day I will drop a "super-post" on you all with my favorite promising evidence for each indication below. Â
Too good to be true? This guy doesn't think so.
APABETALONE (RVX-208) - ONE DRUG - MANY CURES:
Â
Covid19 (and possibly most if not all coronavirus)
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Alzheimer Disease (AD)
DIABETES MILITUSÂ (DM)
FABRY DISEASE
COLORECTAL CANCER
LIVER CANCER
OVARIAN CANCER (Chemotherapy resistant)
HIV-1 (AIDS)
MUSCULAR DYSTROPHY (FSHD)
RESTENOSIS
Osteoporosis
Friedreich’s Ataxia
Thrombosis
Pulmonary arterial hypertension PAH
Degenerative diseases of the eye (retinal)
PERIODONTAL DISEASES
NASH (non-alcoholic steatohepatitis)
ASTHMA
Paroxysmal nocturnal hemoglobinuria (PNH)
ARTHRITIS
Calciphylaxis
Complement Mediated Disease
Neurofibromatosis - Malignant Peripheral Nerve Sheath Tumors (MPNST)
Sepsis, sepsis shock and MODS (Multiple Organ Dysfunction Syndrome in Sepsis)
Apabetalone (also known as RVX-208 or RVX-000222), an oral BETi selective for BD2 within BETs, is currently used in phase 3 clinical trials for the treatment of coronary artery disease, diabetes, and chronic kidney failure. In a mouse model of lethal endotoxemia, apabetalone prevents liver damage by inhibiting the expression of alpha-2-macroglobulin and serum amyloid P. In patients with cardiovascular disease, apabetalone provides benefit for limiting chronic cytokine signaling (Wasiak et al., 2020). Thus, this action of apabetalone might also serve as an effective therapy in treating patient with sepsis and MODS, especially sepsis-induced cardiomyopathy. BRD2 is a direct target of apabetalone (Gordon et al., 2020). Since apabetalone can inhibit the expression of angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the SARS-CoV-2 particles to gain entry into human cells, it is becoming a promising drug for the treatment of COVID-19 and concomitant sepsis (Gilham et al., 2020). RVX-297, a 4-quinazolinone derivative related to RVX-208, is two times more selective for BD2 than RVX-208. RVX-297 also decreases the production of multiple cytokines in endotoxemic mice (Jahagirdar et al., 2017), highlighting its potential anti-inflammatory activities in lethal infection.
Promises🎶